Skip to main content

Advertisement

Table 1 Mean or number (%). Range (Min-Max) and ANOVA of demographic and clinical baseline characteristics of groups

From: Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial

Characteristic   Groups  
Total (n = 40) Experimental (n = 20) Control (n = 20) F (p)
Age (yr). mean (Range) 66.30 (50–82) 67.80 (50–82) 64.80 (54–81) 0.95 (0.33)
Marital Status. number (%)
 Single 5 (12.5) 3 (15) 2 (10)  
 Married 19 (47.5) 14 (70) 5 (25)  
 Divorced/Separated 6 (15) 0 (0) 6 (30)  
 Widow 10 (25) 3 (15) 7 (35)  
Education level. Number (%)
 Any study 11 (27.5) 7 (35) 4 (20)  
 Primary/ Secondary School 16 (40) 7 (35) 9 (45)  
 Vocational training/ Qualifications 8 (20) 3 (15) 5 (25)  
 University/ Superior education 5 (12.5) 3 (15) 2 (10)  
Employed. number (%) 9 (22.5) 3 (15) 6 (30)  
Weight (Kg). mean. (Range)* 72.98 (44–130) 72.71 (53.2–97) 73.25 (44–130) 0.01 (0.91)
Height (cm). mean. (Range)* 159.60 (147–171) 159.25 (148–170) 159.95 (147–171) 0.11 (0.74)
Body Mass Index (BMI). mean. (Range) 28.17 (16.17–47.79) 28.80 (20.70–39.91) 28.62 (16.17–47.79) 0.01 (0.92)
Overweight (BMI ≥ 25). number (%) 30 (75) 14 (70) 16 (80)  
Waist perimeter (cm.). mean. (Range) 97.63 (68–147) 95.80 (75–120) 99.45 (68–147) 0.69 (0.41)
Hip perimeter (cm). mean. (Range) 110.19 (89–145) 111.85 (93–130) 108.53 (89–145) 0.72 (0.40)
Tumor grade. Number (%)
 Grade I 8 (20) 6 (30) 2 (10)  
 Grade II 16 (40) 9 (45) 7 (35)  
 Grade III 14 (35) 5 (25) 9 (45)  
 Grade IV 2 (5) 0 (0) 2 (10)  
Kind of treatments. Number (%)
 Surgery (S) 3 (7.5) 3 (15) 0 (0)  
 S+ Chemotherapy (ChT) 3 (7.5) 0 (0) 3 (15)  
 S+ Radiotherapy (RT) 15 (37.5) 10 (50) 5 (25)  
 S+ ChT+ RT 19 (47.5) 7 (35) 12 (60)  
Previous Tamoxifen (TMX). number (%) 9 (22.5) 3 (15) 6 (30)  
TMX treatment duration (mo). mean. (Range) 4.46 (0–32) 4.30 (0–32) 4.64 (0–25) 0.01 (0.91)
Aromatase Inhibitors (AIs). number (%)
 Anastrozole (Arimidex®) 12 (30) 4 (20) 8 (40)  
 Letrozole (Femara®) 23 (57.5) 14 (70) 9 (45)  
 Exemestane (Aromasin®) 5 (12.5) 2 (10) 3 (15)
AIs treatment duration (mo). mean. (Range) 17.40 (2–52) 15.25 (2–52) 19.55 (2–44) 1.25 (0.27)
Comorbidities. number (%)
 Cervical pain 33 (82.5) 19 (95) 14 (70)  
 Shoulder pain 34 (85) 18 (90) 16 (80)  
 Lumbar pain 30 (75) 17 (85) 13 (65)  
 Hands/ Wrist pain 25 (62.5) 12 (60) 13 (65)  
 Hypertension 24 (60) 14 (70) 10 (50)  
 Heart disease 8 (20) 3 (15) 5 (25)  
 Circulation problems 23 (57.5) 12 (60) 11 (55)  
 Thyroid problems 6 (15) 4 (20) 2 (10)  
 Stroke 0 (0) 0 (0) 0 (0)  
 Diabetes 5 (12.5) 2 (10) 3 (15)  
 Gastric/ duodenal ulcer 1 (2.5) 0 (0) 1 (5)  
 Breathing problems 6 (15) 2 (10) 4 (20)  
 Parkinson 0 (0) 0 (0) 0 (0)  
 Cognitive impairment 0 (0) 0 (0) 0 (0)  
 Migraine/chronic headache 7 (17.5) 4 (20) 3 (15)  
 Vision problems 13 (32.5) 7 (35) 6 (30)  
 Hearing problems 10 (25) 6 (30) 4 (20)  
Lymphedema 4 (10) 2 (10) 2 (10)  
  1. *Self-reported weight and height